Trial Profile
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Eli Lilly and Company
- 08 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2014 New trial record